Association of Lp-PLA 2 activity with allele-specific Lp(a) levels in a bi-ethnic population

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 526-530

  Enkhmaa, Byambaa ^a   Anuurad, Erdembileg ^a   Zhang, Wei ^a   Pearson, Thomas A ^c   Berglund, Lars ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Allele specific apo(a); Ethnicity; K4 repeats; Lipoprotein; Vascular inflammation marker

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B100; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; ARTICLE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVITY; ETHNICITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AFRICAN AMERICANS; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ALLELES; APOLIPOPROTEIN B-100; CHOLESTEROL, HDL; CHOLESTEROL, LDL; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 77955270643     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.03.021     Document Type: Article

References (30)

1. Ballantyne C., Cushman M., Psaty B., et al. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil 2007, 14:3-11.
2. Garza C.A., Montori V.M., McConnell J.P., et al. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007, 82:159-165.
3. El-Saed A., Sekikawa A., Zaky R.W., et al. Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese men. J Epidemiol 2007, 17:179-185.
4. Brilakis E.S., Khera A., McGuire D.K., et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study. Atherosclerosis 2008, 199:110-115.
5. Tselepis A.D., Dentan C., Karabina S.A., et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995, 15:1764-1773.
6. +)-induced oxidative modification in vitro. Atherosclerosis 1996, 125:121-134.
7. Blencowe C., Hermetter A., Kostner G.M., et al. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995, 270:31151-31157.
8. Tsimikas S., Tsironis L.D., Tselepis A.D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2094-2099.
9. Boerwinkle E., Leffert C.C., Lin J., et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992, 90:52-60.
10. McLean J.W., Tomlinson J.E., Kuang W.J., et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
11. Paultre F., Pearson T.A., Weil H.F., et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and white men. Arterioscler Thromb Vasc Biol 2000, 20:2619-2624.
12. Holmer S.R., Hengstenberg C., Kraft H.G., et al. Association of polymorphisms of the apolipoprotein(a) gene with lipoprotein(a) levels and myocardial infarction. Circulation 2003, 107:696-701.
13. Rifai N., Ma J., Sacks F.M., et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem 2004, 50:1364-1371.
14. Rubin J., Kim H.J., Pearson T.A., et al. Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. J Lipid Res 2006, 47:982-989.
15. Marcovina S.M., Albers J.J., Wijsman E., et al. Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans. J Lipid Res 1996, 37:2569-2585.
16. Anuurad E., Lu G., Rubin J., et al. ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: the Harlem-Basset Study. J Lipid Res 2007, 48:693-698.
17. Anuurad E., Rubin J., Chiem A., et al. High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans. J Clin Endocrinol Metab 2008, 93:1482-1488.
18. Packard C.J., O'Reilly D.S., Caslake M.J., et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 2000, 343:1148-1155.
19. Lavi S., McConnell J.P., Rihal C.S., et al. Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans. Circulation 2007, 115:2715-2721.
20. + precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982, 28:1379-1388.
21. Lackner C., Cohen J.C., Hobbs H.H. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993, 2:933-940.
22. Rubin J., Paultre F., Tuck C.H., et al. Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res 2002, 43:234-244.
23. Kiechl S., Willeit J., Mayr M., et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007, 27:1788-1795.
24. Tsimikas S., Clopton P., Brilakis E.S., et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009, 119:1711-1719.
25. Yamada Y., Yoshida H., Ichihara S., et al. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis 2000, 150:209-216.
26. Hiramoto M., Yoshida H., Imaizumi T., et al. A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke 1997, 28:2417-2420.
27. Yamada Y., Izawa H., Ichihara S., et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002, 347:1916-1923.
28. Yamada Y., Metoki N., Yoshida H., et al. Genetic risk for ischemic and hemorrhagic stroke. Arterioscler Thromb Vasc Biol 2006, 26:1920-1925.
29. Abuzeid A.M., Hawe E., Humphries S.E., et al. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis 2003, 168:283-288.
30. Stafforini D.M., Tjoelker L.W., McCormick S.P., et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999, 274:7018-7024.